Clinical trials
Phase 2 Arthralgia trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
31 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 4 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2021 | 5 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 13 |
| Terminated | 7 |
| Unknown status | 5 |
| Recruiting | 3 |
| Withdrawn | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AHS Cancer Control Alberta | 2 |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2 |
| Novartis Pharmaceuticals | 2 |
| Amgen | 1 |
| Baylor Breast Care Center | 1 |
| Centocor, Inc. | 1 |
| Dawn L. Hershman | 1 |
| Erin Newton | 1 |
| Eskisehir Osmangazi University | 1 |
| GlaxoSmithKline | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Arthralgia | 31 |
| Arthritis | 8 |
| Pain | 7 |
| Breast Neoplasms | 6 |
| Osteoarthritis | 5 |
| Arthritis, Rheumatoid | 3 |
| Myalgia | 3 |
| Osteoarthritis, Knee | 3 |
| Abdominal Pain | 1 |
| Anosmia | 1 |
Trials
Showing 51 to 31 of 31. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.